Robert Jasmer, MD
Pulmonary Disease · Burlingame, CANPI 1891746574
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Insmed, Inc. at 43.5% of the total. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 712 payments — averaging $137.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$43K
- Boehringer Ingelheim$36K
- AstraZeneca$9K
- GSK$3K
- Mylan Specialty L.p.$1K
- Bayer$756
- plus $6K from 41 others
What the payments were for
- Consulting fees$42,84944%
- Speaking & faculty fees$29,11830%
- Travel & lodging$8,5659%
- Food & beverage$17,30518%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$33,632
- OFEV$10,061
- Brinsupri$3,804
- BREZTRI$1,343
- Yupelri$870
- Adempas$725
- FLOWTRIEVER CATHETER, S$145
- CT THROMBECTOMY SYSTEM KIT$145
- NUCALA$122
- 3F$113
How this compares
$97,872 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $385,895 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 302 | $291,668 |
| Pirfenidone | 34 | $106,028 |
| EliquisApixaban | 85 | $67,871 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $61,690 |
| Spiriva RespimatTiotropium Bromide | 75 | $50,553 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $42,913 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $33,819 |
| XareltoRivaroxaban | 26 | $29,697 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $21,452 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $18,433 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $16,503 |
| Ambrisentan | 13 | $16,169 |
| Spiriva HandihalerTiotropium Bromide | 13 | $10,766 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $9,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $35,816 | $495,865197 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,683 | $364,897455 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $8,551 | $84,822152 claims |
| PfizerEliquis | $116 | $67,87185 claims |
| Johnson & JohnsonXarelto | $216 | $29,69726 claims |
| MerckDulera, Asmanex | $350 | $12,13329 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $43 | $4,99119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Burlingame
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.